Ageing research reviews · 2026
In vitro cell-line models of Alzheimer's disease: A systematic review and mechanism-based evidence map of induction paradigms, targeted mechanisms, and validation requirements.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alghamdi Hajar
Аннотация
BACKGROUND: In vitro cell-line models are essential for investigating the complex, interconnected mechanisms of Alzheimer's disease (AD). While offering high tractability for mechanism-focused screening, their translational utility depends on the precise alignment of the biological inquiry with the appropriate cellular system, induction strategy, and experimental readouts.
METHODS: This systematic review and mechanism-based evidence map searched PubMed (inception to 1 May 2026), capturing 93 original experimental studies across neuronal, glial, endothelial, and higher-fidelity multicellular systems. Extracted data were structured by cellular model, induction paradigm, targeted mechanism, and interpretive scope.
RESULTS: The synthesized evidence indicates that AD-relevant in vitro systems are not interchangeable whole-disease models, but mechanism-based tools. SH-SY5Y cells are primarily suited for Aβ-associated neuronal toxicity and general screening. Neuro-2a (N2a) systems are optimized for evaluating APP processing and amyloidogenesis. HT-22 cells specifically model oxidative glutamate toxicity and ferroptosis-related injury, while PC12 cells are strictly reserved for NGF-dependent neurite biology and neuroprotection.
CONCLUSIONS: While classical cell lines remain essential for initial mechanistic screening, establishing disease-level relevance requires validation through orthogonal readouts and high-fidelity human models, such as multicellular organoids or blood-brain barrier systems.
METHODS: This systematic review and mechanism-based evidence map searched PubMed (inception to 1 May 2026), capturing 93 original experimental studies across neuronal, glial, endothelial, and higher-fidelity multicellular systems. Extracted data were structured by cellular model, induction paradigm, targeted mechanism, and interpretive scope.
RESULTS: The synthesized evidence indicates that AD-relevant in vitro systems are not interchangeable whole-disease models, but mechanism-based tools. SH-SY5Y cells are primarily suited for Aβ-associated neuronal toxicity and general screening. Neuro-2a (N2a) systems are optimized for evaluating APP processing and amyloidogenesis. HT-22 cells specifically model oxidative glutamate toxicity and ferroptosis-related injury, while PC12 cells are strictly reserved for NGF-dependent neurite biology and neuroprotection.
CONCLUSIONS: While classical cell lines remain essential for initial mechanistic screening, establishing disease-level relevance requires validation through orthogonal readouts and high-fidelity human models, such as multicellular organoids or blood-brain barrier systems.